Establishment of Prostate Cancer Organoids
The short term primary prostate cancer patient derived organoids will be of great added value in early drug screens and personalized medicine, as in vitro testing of subsequent treatment options might predict patient responses and therefore allowing guidance of clinical decision making.
Van Hemelryk A.1, Teubel W.J.1, de Ridder C.M.A.1, Erkens-Schulze S.1, Mout L.1, van Royen M.E.2, van Weerden W.M.1
1Erasmus University Medical Center, Department of Urology, Rotterdam, The Netherlands
2Erasmus University Medical Center, Department of Pathology, Rotterdam, The Netherlands
- The optimal treatment strategy regarding first line and subsequent treatments for CRPC remains unclear, giving rise to interpatient heterogeneity in resistance profiles.
- To date, preclinical (CR)PC models are scarce and insufficiently represent current clinical disease
- We aim to establish an extensive in vitro 3D organoid panel that allows to test, develop, optimize and ultimately personalize treatment strategies.
MATERIALS AND METHODS
- We set up 3D organoid cultures of prostate cancer
- cell lines,
- patient derived xenografts (PDX) and
- primary patient tissue originating from (CR)PC patients undergoing palliative transurethral resection of the prostate.
- Single cells and small cell clumps were plated in Matrigel or Noviogel (Noviocell, Oss, The Netherlands).
- Organoids were cultured in prostate cancer growth medium (PGM) (Marques et al., 2005) and organoid medium adapted from Drost et al., 2016.
CELL LINE DERIVED ORGANOIDS (a) Bright field images of PC346C organoids, 14 days after plating in Noviogel-P5K (left) and Matrigel (right). (b) H&E staining of PC346C organoids, at 400x magnification. (c) Bright field images of PC339C organoids, 7 days after plating in Noviogel-P5K left) and Matrigel (right).
More results about the establishment of prostate cancer organoids in the poster presented at the conference ESUR 2018.